A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
Launched by HAISCO PHARMACEUTICAL GROUP CO., LTD. ·
Trial Information
Current as of September 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new oral medicine called HSK44459 to see if it is safe and helpful for adults with moderate to severe plaque psoriasis, a common skin condition that causes red, scaly patches. The goal is to find out if this medicine can improve the symptoms of psoriasis and how well people tolerate it.
Adults aged 18 to 74 with moderate to severe plaque psoriasis may be able to join the study. Participants will take the medicine by mouth and will be monitored by doctors to check how their skin responds and to watch for any side effects. The study is not yet recruiting, so if you or a loved one is interested, it’s important to stay in touch with your healthcare provider for updates. This trial offers a chance to try a new treatment under close medical supervision.
Gender
ALL
Eligibility criteria
About Haisco Pharmaceutical Group Co., Ltd.
Haisco Pharmaceutical Group Co., Ltd. is a leading biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative therapeutic solutions. Headquartered in China, Haisco specializes in a broad range of pharmaceutical products, with a strong emphasis on oncology, cardiovascular, and infectious diseases. Committed to advancing healthcare, Haisco integrates cutting-edge technology and extensive clinical expertise to develop high-quality medications that address unmet medical needs. The company is focused on fostering strategic partnerships and expanding its global reach through rigorous clinical trials and a robust pipeline of novel therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported